ATE253941T1 - Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden - Google Patents

Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden

Info

Publication number
ATE253941T1
ATE253941T1 AT98928901T AT98928901T ATE253941T1 AT E253941 T1 ATE253941 T1 AT E253941T1 AT 98928901 T AT98928901 T AT 98928901T AT 98928901 T AT98928901 T AT 98928901T AT E253941 T1 ATE253941 T1 AT E253941T1
Authority
AT
Austria
Prior art keywords
active ingredients
decomposed
composition
water
storage stability
Prior art date
Application number
AT98928901T
Other languages
English (en)
Inventor
Stella J Valentino
Original Assignee
Cydex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Inc filed Critical Cydex Inc
Application granted granted Critical
Publication of ATE253941T1 publication Critical patent/ATE253941T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98928901T 1997-06-13 1998-06-12 Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden ATE253941T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5090997P 1997-06-13 1997-06-13
PCT/US1998/011596 WO1998056422A1 (en) 1997-06-13 1998-06-12 Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof

Publications (1)

Publication Number Publication Date
ATE253941T1 true ATE253941T1 (de) 2003-11-15

Family

ID=21968241

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98928901T ATE253941T1 (de) 1997-06-13 1998-06-12 Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden

Country Status (9)

Country Link
US (1) US6133248A (de)
EP (1) EP0986403B1 (de)
JP (1) JP4439596B2 (de)
AT (1) ATE253941T1 (de)
AU (1) AU750207B2 (de)
DE (1) DE69819721T2 (de)
ES (1) ES2210769T3 (de)
PT (1) PT986403E (de)
WO (1) WO1998056422A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100856523B1 (ko) * 2000-08-03 2008-09-04 안타레스 파르마 아이피엘 에이쥐 충분한 치료효과를 보장하는 활성 화합물의 경피 및/또는경점막 투여용 신규 조성물
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
US6566556B2 (en) * 2000-12-19 2003-05-20 Nippon Shokubai Co., Ltd. Method for production of alkanolamine and apparatus therefor
JP2004522803A (ja) * 2001-06-29 2004-07-29 マキシゲン・エイピーエス インターフェロン製剤
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
PT1456377T (pt) * 2001-12-20 2019-09-10 Merck Sharp & Dohme Composições de syn3 e processos
MXPA04008173A (es) * 2002-02-22 2004-11-26 Pharmacia Corp Formulaciones de farmaco antibiotico oftalmico que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio.
AR038575A1 (es) * 2002-02-22 2005-01-19 Pharmacia Corp Formulacion oftalmica con nueva composicion de goma
JP5619337B2 (ja) 2003-10-10 2014-11-05 フェリング ビー．ブイ． 皮膚残渣を最小限に抑えるための経皮的医薬製剤
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
CN103554222A (zh) 2004-04-15 2014-02-05 欧尼斯治疗公司 用于抑制蛋白酶体酶的化合物
SI2030981T1 (sl) * 2004-05-10 2014-11-28 Onyx Therapeutics, Inc. Spojine za inhibiranje proteasomskega encima
PT2261236E (pt) * 2004-12-07 2015-10-30 Onyx Therapeutics Inc Composição para a inibição de proteassoma
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
AU2006311584B2 (en) 2005-11-09 2012-03-08 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
US20070111965A1 (en) * 2005-11-15 2007-05-17 Kipp James E Compositions comprising lipoxygenase inhibitors and cyclodextrin
US20070135586A1 (en) * 2005-12-09 2007-06-14 Shreyas Chakravarti Polyamide blend compositions formed article and process thereof
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
AU2007261345B2 (en) 2006-06-19 2012-02-23 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
US20080194519A1 (en) * 2006-09-15 2008-08-14 Regents Of The University Of Minnesota Topiramate compositions and methods for their use
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
RU2470636C2 (ru) 2007-04-27 2012-12-27 Сайдекс Фамэсьютиклз, Инк. Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты)
WO2009018326A2 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Soluble pyrone analogs methods and compositions
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
EP2303228B1 (de) * 2008-05-19 2011-11-30 Texcontor Etablissement Fosphenytoin-zusammensetzung
CA2741312C (en) 2008-10-21 2020-10-27 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
PT3100728T (pt) 2009-05-13 2020-02-21 Cydex Pharmaceuticals Inc Composições farmacêuticas que compreendem prasugrel e derivados da ciclodextrina e métodos de produção e utilização dos mesmos
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
US20100311838A1 (en) 2009-05-29 2010-12-09 Pipkin James D Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same
PT2445502T (pt) 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
AU2010266040B2 (en) 2009-06-25 2015-01-15 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
SG183843A1 (en) 2010-03-01 2012-10-30 Onyx Therapeutics Inc Compounds for immunoproteasome inhibition
MX2012011604A (es) 2010-04-07 2013-02-27 Onyx Therapeutics Inc Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino.
CA2802733C (en) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
DE102011011028A1 (de) * 2011-02-11 2012-08-16 Ditter Plastic Gmbh + Co. Kg Frontplatte mit darin eingespritztem Lichtleiter
RU2627469C2 (ru) 2011-03-18 2017-08-08 Алкермес Фарма Айэленд Лимитед Фармацевтические композиции, содержащие водонерастворимое антипсихотическое средство и сложные эфиры сорбита
US9376395B2 (en) 2011-09-18 2016-06-28 Purdue Pharmaceuticals Products L.P. Pharmaceutical compositions
EP2790734B1 (de) 2011-12-15 2019-02-20 Alkermes Pharma Ireland Limited Prodrugs von sekundären aminverbindungen
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
CN104271605B (zh) 2012-02-15 2017-07-25 锡德克斯药物公司 环糊精衍生物的制造方法
JP2015508846A (ja) 2012-02-28 2015-03-23 サイデックス・ファーマシューティカルズ・インコーポレイテッド アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
NZ630428A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
NZ748572A (en) 2012-09-19 2020-07-31 Alkermes Pharma Ireland Ltd Pharmaceutical compositions having improved storage stability
BR112015008954B1 (pt) 2012-10-22 2021-03-02 Cydex Pharmaceuticals, Inc processos para preparar uma composição de ciclodextrina alquilatada compreendendo uma ciclodextrina alquilatada, para preparar pelo menos 9 lotes consecutivos da mesma e para preparar uma composição farmacêutica
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
FI3183295T3 (fi) 2014-08-22 2023-09-25 Cydex Pharmaceuticals Inc Fraktioidut alkyloidut syklodekstriinikoostumukset ja menetelmät niiden valmistamiseksi ja käyttämiseksi
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
CA3040155C (en) 2016-10-11 2024-01-16 Euro-Celtique S.A. Compound for use in the treatment of hodgkin lymphoma
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
AU2019230014A1 (en) 2018-03-05 2020-09-17 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
CN110279664B (zh) * 2019-07-30 2021-09-03 四川农业大学 一种氟苯尼考包合物冻干粉针剂及其制备方法
EP4010031A1 (de) 2019-08-06 2022-06-15 L.E.A.F Holdings Group LLC Verfahren zur herstellung von polyglutamat-antifolaten und ihre verwendungen
EP4257120A4 (de) * 2020-12-04 2024-08-07 Sichuan Credit Pharmaceutical Co Ltd Feste fosphenytoin-natrium-zusammensetzung, lyophilisierungsverfahren und verwendung der festen fosphenytoin-natrium-zusammensetzung
CN118161457A (zh) * 2020-12-04 2024-06-11 四川科瑞德制药股份有限公司 磷苯妥英钠固体组合物、冻干方法、及其用途
WO2023225113A1 (en) * 2022-05-18 2023-11-23 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
US4616008A (en) * 1984-05-02 1986-10-07 Takeda Chemical Industries, Ltd. Antibacterial solid composition for oral administration
JPS61165322A (ja) * 1985-01-14 1986-07-26 Microbial Chem Res Found スパガリン類の注射用凍結乾燥製剤
US4728509A (en) * 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
US4925860A (en) * 1987-08-05 1990-05-15 E. I. Du Pont De Nemours And Company Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester
DE3938227C1 (en) * 1989-11-17 1991-05-02 Dolorgiet Gmbh & Co Kg, 5205 St Augustin, De Oral antiinflammatory and analgetic pharmaceutical compsn. - comprises magnesium ibuprofen dissolved in mixt. of water, propane-1,2-diol and glycerol
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
DE839528T1 (de) * 1996-10-29 1998-10-22 Staroil Ltd Mundlösliche Zusammensetzungen die N-Acetylcystein und Cyclodextrin enthalten

Also Published As

Publication number Publication date
ES2210769T3 (es) 2004-07-01
AU750207B2 (en) 2002-07-11
DE69819721D1 (de) 2003-12-18
DE69819721T2 (de) 2004-09-23
US6133248A (en) 2000-10-17
EP0986403B1 (de) 2003-11-12
AU8059198A (en) 1998-12-30
JP2002511861A (ja) 2002-04-16
JP4439596B2 (ja) 2010-03-24
WO1998056422A1 (en) 1998-12-17
EP0986403A1 (de) 2000-03-22
PT986403E (pt) 2004-04-30

Similar Documents

Publication Publication Date Title
ATE253941T1 (de) Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden
ATE262308T1 (de) Kosmetische oder pharmazeutische zusammensetzung in form eines feststoffs, welche verformt werden kann
ES2190075T3 (es) Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.
DE69942154D1 (de) Medikamenthaltige zusammensetzung in aerosolform
FR2451192A1 (fr) Agent de prevention de la mauvaise haleine contenant de la cyclodextrine
EP1283054A4 (de) Medikamente zur behandlung von komplikationen des diabetes und neuropathien, und verwendung davon
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
ATE179884T1 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
ATE226815T1 (de) Herstellung von arzneimitteln
PH22075A (en) New complex compounds of piroxicam with cyclodextrin having antiinflammatory activity and pharmaceutical compositions containing them
ATE370730T1 (de) Pharmazeutische zubereitungen, die chelatbildner/sequestriermittel enthalten und deren dermatologische verwendung
BG101141A (en) Fungicidal composition and method for fungous disease control
AU2412695A (en) Taxane class derivative based pharmaceutical compositions
BR9809057A (pt) Composições antitussìgenas
TW345496B (en) Skin care composition containing retinol
ATE254922T1 (de) Pharmazeutische zusammensetzungen mit antimikrobieller wirkung
EP0931545A3 (de) Droloxifen pharmazeutische Zusammenstellung
KR940011014A (ko) 안정화된 수퍼옥사이드 디스뮤타아제(sod) 조성물
ATE363909T1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
ATE173624T1 (de) Synergistische pharmazeutische zusammensetungen, die triamcinolonacetonid und halcinonid enthalten
TW372193B (en) Novel pharmaceutical composition for the preparation of a stable powder containing an association of acetylsalicylic acid and metoclopramide as the active ingredient
ATE328569T1 (de) Wasserfreie schweisshemende oder desodorierende zusammensetzungen enthaltend einen festen, wasserlöslichen hautpflegenden wirkstoff und glycerin
FR2635463B1 (de)
BG106368A (en) Pharmaceutical composition and its preparation
BR9608721A (pt) Composição farmacêutica, e, processo para tratar inflamação

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0986403

Country of ref document: EP

EEFA Change of the company name